168
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Biological determinants of endocrine resistance in breast cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signalling in endocrine resistance. However, definition of the specific genetic lesions and molecular processes that determine clinical endocrine resistance is incomplete. The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.

          Related collections

          Author and article information

          Journal
          Nat Rev Cancer
          Nature reviews. Cancer
          Springer Science and Business Media LLC
          1474-1768
          1474-175X
          Sep 2009
          : 9
          : 9
          Affiliations
          [1 ] Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia. e.musgrove@garvan.org.au
          Article
          nrc2713
          10.1038/nrc2713
          19701242
          284760b1-6132-432d-857b-300c524b86dc
          History

          Comments

          Comment on this article